Thanks SG. I think one question is "did the R

Thanks SG.

I think one question is "did the Remdesivir trial meet an endpoint with statistical significance in a randomized double blind clinical trial?" If it did, then your statement wouldn't be accurate. (By they way, this might be the only trial worth checking on. Maybe the one in India also for itolimuzab (sp).)

We all say, and believe, that "Remdesivir changed the endpoint." That may be true. But, if they changed it and met it, then is your statement accurate?

I'm not arguing with you. Just trying to see if we can factually be confident in your statement. As I said, if accurate, it should basically be the headline of news stories: "[Leronlimab is] the first drug on earth to meet any endpoint in a COVID-19 randomized double blind clinical trial."

Read More: https://investorshangout.com/post/view?id=585...z6UxhYiq8k

This story provide some clues, but not proof either way that I could find: https://www.statnews.com/2020/05/11/inside-th...vir-study/